Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 16.63M P/E - EPS this Y -6.00% Ern Qtrly Grth -
Income -15.75M Forward P/E -0.89 EPS next Y - 50D Avg Chg 4.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 7.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -42.00%
Recommedations 2.00 Quick Ratio 3.79 Shares Outstanding 10.20M 52W Low Chg 58.00%
Insider Own 26.67% ROA -71.12% Shares Float 7.48M Beta 1.16
Inst Own 5.88% ROE -127.04% Shares Shorted/Prior 3.66K/8.08K Price 1.98
Gross Margin - Profit Margin - Avg. Volume 12,253 Target Price -
Oper. Margin - Earnings Date Aug 12 Volume 10,849 Change -2.94%
About Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Indaptus Therapeutics, Inc. News
09/05/24 Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
09/03/24 Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/12/24 Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
08/11/24 Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m
08/07/24 Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
06/11/24 Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit
06/04/24 Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
06/03/24 Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20
05/30/24 Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference
05/29/24 Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting
05/22/24 Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors
05/08/24 Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/11/24 Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
03/28/24 Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
03/25/24 Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
03/18/24 Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
03/13/24 Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
03/04/24 Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
02/15/24 Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
02/08/24 Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
INDP Chatroom

User Image GoGetIT0 Posted - 12 hours ago

$INDP Anyone notice that insiders haven't purchased any shares in what feels like a couple years? Why do you think that is?

User Image Tomekk Posted - 14 hours ago

$INDP the pump possible this autumn, like in good old days. We are ready.

User Image Tomekk Posted - 20 hours ago

$INDP rate cuts+Indaptus = tendies

User Image aztecb Posted - 1 day ago

$INDP https://twitter.com/indaptus/status/1836430428246270407?s=46&t=LI1VS7B4JjWYiX102u0yZw

User Image aztecb Posted - 3 days ago

$INDP https://twitter.com/indaptus/status/1835678730213048395?s=46&t=LI1VS7B4JjWYiX102u0yZw

User Image CalmChronos Posted - 1 week ago

$INDP Good long term set up

User Image Biomechanika Posted - 1 week ago

$INDP Ph1b combination therapies for safety data will start first half of next year.

User Image AverageAndy Posted - 1 week ago

$INDP One of my worst investments. Please prove me wrong.

User Image aztecb Posted - 1 week ago

$INDP I’ve seen a tarts knickers drop slower than this 😂

User Image aztecb Posted - 1 week ago

$INDP Yep this does not surprise me in slightest. Guess I was right 😂

User Image aztecb Posted - 2 weeks ago

$INDP I’ve purchased 7000 shares over the last 24hrs. Have I brought at the bottom ? I very much doubt it 😂 However it’s always fun averaging down with this one.

User Image aztecb Posted - 2 weeks ago

$INDP unbelievable Geoff….. unbelievable

User Image AZOZ Posted - 2 weeks ago

$INDP Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

User Image HorsePicks Posted - 2 weeks ago

$INDP Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

User Image Stock_Titan Posted - 2 weeks ago

$INDP Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses https://www.stocktitan.net/news/INDP/indaptus-therapeutics-reports-encouraging-new-safety-data-for-8at80b8jww8k.html

User Image aztecb Posted - 2 weeks ago

$INDP brought another 5000 yesterday 🥳

User Image VJay_18 Posted - 2 weeks ago

$INDP If they deliver any news regarding the combination of Decoy 20 with low dose chemo or partnering with well established Cancer Players would be nice to hear

User Image GoGetIT0 Posted - 2 weeks ago

$INDP from bad to worse.... This cannot be a real company, right? Knock knock, anyone home?!?! How is it even possible that they are allowed to be listed on the NASDAQ? TT

User Image Biomechanika Posted - 2 weeks ago

$INDP

User Image PennyStocksMom Posted - 08/30/24

⏳️⏳️Potential swing ideas 💡 ✅️✅️ $BBAI recently announced providing services to Concept Solutions, a private company recently awarded a long-term contract with the FAA, recent runner, insider/independent purchased: 1) Director, Pamela Braden recently purchased $210k worth at $1.49 per share, 2) Avishay Katz bought average $2.64 /share worth $620k in the last 12 months, Cantor Fitzgerald pt $3, previously announced extending deal with US Army for GFIM system worth $17.9M, also expanded its partnership with $AMZN division Web Services (AWS), which will enable AWS's customers to benefit from BBAI's warehousing solution to deliver AI-Driven solutions, customers including U.S Intelligence community, Department of Defense, and US. Federal Government ✅️ $INDP company focuses on developing novel treatments for cancer and infectious diseases, Recently announced positive data from ongoing phase 1 trial of Decoy20, Maxim Group pt $8, HC Wainwright pt $12 🎯Goal is Green 🤑 not Greed 🥵

User Image GoGetIT0 Posted - 08/29/24

$INDP this company cannot be actually conducting business anymore, right? We were supposed to receive phase 1 multi dose update every 4-6 weeks, for the three patients. It has been nearly 6 months and only 1 update was provided on 1 patient. Meanwhile they raised more money through an offering. My guess is that offering was one final bonus payout to each executive before they close the doors. This company should have never been publicly traded.... There seems to be a few people who will be very unfortunate here

User Image Biomechanika Posted - 08/27/24

$INDP

User Image Manipulation13F Posted - 08/23/24

$INDP Gap filled on the 1 hr volume increasing a bit im ready 😎

User Image GoGetIT0 Posted - 08/22/24

$INDP 👇#aztecb what a clown. Thought he wanted to to drop to buy more shares... Lol

User Image aztecb Posted - 08/22/24

$INDP 😔 that’s all I’ve got to say.

User Image RallyRaider Posted - 08/21/24

$INDP YIKES please more videos on the youtube channel ! AIG)§%!=§%)=H9s

User Image aztecb Posted - 1 month ago

$INDP Nearky a year since an update. https://www.clinicaltrials.gov/study/NCT05651022?cond=NCT05651022&rank=1&tab=history&a=8

User Image Indpwhenhigh Posted - 1 month ago

$INDP You'll beg to take what I have. Hahaha

User Image AverageAndy Posted - 1 month ago

$INDP WE NEED SOME REALLY GOOD NEWS!

User Image PenkeTrading Posted - 1 month ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Indaptus Therapeutics Inc. Is that bullish or bearish? $INDP #INDP #nasdaq #tradingsignals #technicalanalysis

Analyst Ratings
HC Wainwright & Co. Buy Jun 17, 24
HC Wainwright & Co. Buy Apr 15, 24
HC Wainwright & Co. Buy Sep 20, 23
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy Aug 8, 23
HC Wainwright & Co. Buy May 4, 23
HC Wainwright & Co. Buy Mar 20, 23
HC Wainwright & Co. Overweight Mar 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anderson Glen R. 10% Owner 10% Owner Aug 10 Buy 2.13 103,352 220,140 1,190,400 08/16/23
Litchev Boyan Vesselinov Chief Medical Office.. Chief Medical Officer Jan 31 Buy 3.11 1,150 3,576 1,150 12/19/22
Meckler Jeffrey A CEO and Director CEO and Director Sep 08 Buy 2.80 10,308 28,862 65,374 09/12/22
Linscott Walt Addison Chief Business Offic.. Chief Business Officer Sep 07 Buy 2.62 150 393 150 09/09/22
Meckler Jeffrey A CEO and Director CEO and Director Sep 06 Buy 2.51 9,692 24,327 55,066 09/08/22
Meckler Jeffrey A CEO and Director CEO and Director Jun 06 Buy 2.63 19,727 51,882 45,374 06/07/22
Newman Michael James CSO and Director CSO and Director Jan 31 Sell 5 20,000 100,000 1,368,356 02/02/22